LAKE OSWEGO, Ore.--(BUSINESS WIRE)--BIOTRONIK, a manufacturer of implantable cardiac devices and wireless remote monitoring technologies, has been added to the list of cardiac rhythm management (CRM) device suppliers to the U.S. Department of Veterans Affairs (VA).
BIOTRONIK’s full portfolio of devices and leads are now available on VA contract
“We are honored and excited to bring our portfolio of devices to support the men and women who have served in America’s military services, as well as their families,” said Paul Woodstock, Executive Vice President of Sales, BIOTRONIK, Inc. “We strive to create the best quality products with clinically meaningful innovation, and provide them for the best cost possible. We are thrilled to be included in this contract.”
The Veterans Health Administration is America’s largest integrated health care system with over 1,700 sites of care, serving 8.76 million veterans each year.
One of the world’s leading manufacturers of cardio- and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. The current product portfolio includes the exclusive BIOTRONIK DX System, which provides dual-chamber sensing with a single lead. This latest technology innovation has been shown to reduce lead complications and mortality1, as well as have faster implant procedures and less flouroscopy exposure2 during those procedures.
The BIOTRONIK DX System is only the latest innovation the company offers U.S. patients. BIOTRONIK has pioneered advances in its BIOTRONIK Home Monitoring® remote patient management system since its first clinical application in the year 2000. The system is unique because it allows continuous, automatic wireless remote monitoring of patient status and device status with daily updates — all independent of any patient interaction. The technology leads to earlier intervention, as proven by the results of the TRUST landmark trial. Today, BIOTRONIK Home Monitoring® is used extensively in more than 5,300 clinics and 56 countries worldwide.
1. Dewland, TA. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011 Aug 30;58(10):1007-13. doi: 10.1016/j.jacc.2011.04.039.
2. Chicos AB, Knight BP.Using floating atrial electrodes to combat the rising tide of inappropriate defibrillator therapies. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):5-7. doi: 10.1161/CIRCEP.110.961219.